Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab

Anais Brasileiros de Dermatologia

Isabela Soubhia Corral¹  Thais Helena Proença De Freitas¹  Renata Telles Rudge De Aquino¹  Daniella Abbruzzini S. Koller¹  Maria Elisa Ruffolo Magliari¹  Helena Muller¹ 

关键词: Desmogleins;    Drug resistance;    Pemphigus;    Treatment failure;    Desmogleínas;    Falha de tratamento;    Pênfigo;    Resistência a medicamentos;   

DOI  :  10.1590/abd1806-4841.20131990

来源: SciELO

【 摘 要 】

Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120mg, soon reduced to 20mg.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License